339 pharmaceutical companies sunbathe the first half of the report card! More than 40% performance double down, 43 losses, Hengrui, Murray... Five companies made net profits of more than $2 billion.

Up to now, 339 A-share pharmaceutical enterprises have disclosed the first half of 2020 performance, Shanghai Pharmaceuticals, Kyushua Tong and other 16 revenue of more than 10 billion yuan;
It is worth mentioning that, affected by the outbreak of neo-crown pneumonia, more than 50% of the first quarter of the enterprise performance (revenue, net profit) fell, 53 net profit losses;
first-half results fell to 42 per cent, while 43 pharmaceutical companies lost net profit, compared with 17 in the same period last year.
Net profit TOP10: Meirui Medical, Hengrui Pharmaceuticals, Yunnan White Pharmaceuticals and other 5 more than 2 billion A-share pharmaceutical enterprises in the first half of 2020 net profit TOP10 (units: 100 million yuan) net profit TOP10, Meirui Medical, Hengrui Pharmaceuticals, Yunnan White Pharmaceuticals and other 5 more than 2 billion yuan.
, "Medical Brother" Mei rui medical with 3.454 billion yuan in the first place, Hengrui pharmaceutical followed closely behind, vitamin leading enterprises new and into the net profit growth rate is the fastest, as high as 91.41 percent.
Meirui Medical: The company's first-half net profit exceeded the 3 billion mark, for the performance of the big rise, Meirui Medical said that this year's outbreak of the new crown in the world, so that the company's life information and support business monitors, ventilators, infusion pumps and medical imaging business portable color super and other products demand increased significantly, including life information and support business pull role is particularly significant.
the second quarter of 2020, the company began exporting new coronary antibody reagents to overseas markets, making up for some of the impact of the outbreak on conventional in-body diagnostic reagents.
same time, the company continued to strengthen internal management, improve operating efficiency, coupled with the outbreak period offline marketing promotion activities and travel reduction, operating performance showed a healthy and good growth trend.
addition, with the company's brand influence and awareness in the domestic and international markets has been greatly enhanced, to achieve a number of high-end market customer base breakthroughs, the company's future growth has brought more opportunities.
: First half of the company's revenue and net profit remained double-digit growth.
Hengrui Pharmaceuticals said that the main drivers of performance are two aspects: First, innovation gradually entered the harvest period, which has played a driving role in the company's performance growth, and second, the company's product structure optimization, with the company's product restructuring, the company's non-anti-tumor products represented by the imager to maintain a stable growth trend.
, the company will continue to steadily promote research and development innovation and the internationalization of preparation products, while also focusing on product structure optimization and improvement to ensure sustainable growth of the company's performance.
: This year the company out of the "low", the first half of the net profit has exceeded the full year 2019.
Said that in the face of increased market uncertainty brought about by the outbreak, the company actively responded to seize market opportunities to maximize the value of multiple products.
, the main products of the nutrition and fragrance business achieved a price increase, the nutrition business revenue increased by 54.40 percent, and the fragrance business revenue increased by 15.43 percent.
In addition, the construction of key projects landed, methionine phase II project annual output of 100,000 tons of production line has been put into trial production, marking the company to achieve the annual production of methionine 300,000 tons of development goals have taken a solid step;
gross margin TOP10: all more than 90%, the company accounted for 4 A-share pharmaceutical enterprises in the first half of 2020 gross margin TOP10 gross margin TOP10 are more than 90%, of which, Kanghua bio-gross margin is the highest, up to 95.42%.
addition, micro-core biology, Fudan Zhangjiang, Concino and other 4 from the science and technology board.
: In June this year, the company officially landed on the A-share, with 20 one-word board, one signed profit of more than 250,000 yuan, causing the market's high concern.
data show that the company is a comprehensive research, development, operation of integrated vaccine production enterprises, at the same time for the current domestic production of human secondary cell rabies vaccine enterprises.
the first half of this year, the company's operating income was RMB455 million, up 67.97 percent YoY, while net profit was RMB183 million, up 115.51 percent YoY, and gross margin was 95.42 percent.
Kanghua Bio said that during the outbreak, the company to ensure the smooth resumption of production, vaccine production and sales were not affected by the outbreak, the core product freeze-dried human rabies vaccine (human double body cells) due to market demand and other factors, product sales increased.
Pharmaceuticals: In the first half of the year, the company achieved operating income of RMB952 million, up 24.92% YoY, net profit of RMB144 million, up 64.65% YoY, and gross margin of 92.88 percent.
Bedda Pharmaceuticals said that the rapid growth of performance, on the one hand, the differentiated competitive strategy has a significant effect, in the face of the "4 plus 7" volume procurement and expansion of the implementation of the challenges, the company firmly implemented Ektini's differentiated competitive strategy, the effect is significant; Base drug catalog to promote the sinking of channels, Ektini successfully included in the national health insurance catalog and the national list of essential drugs, the company to promote channel sinking, actively strengthen the development of target hospitals, and strive to improve hospital coverage, while promoting the national pharmacy health insurance access work, fully guarantee the growth of Ektini sales.
revenue TOP10: Shanghai pharmaceutical leader, Kyushua Tong first broke the 50 billion A-share pharmaceutical enterprises in the first half of 2020 revenue TOP10 (units: 100 million yuan) revenue TOP10, 10 pharmaceutical enterprises "threshold" are more than 16 billion yuan, of which, Shanghai Pharmaceuticals with 87.2 billion yuan, Kyushuan for the first time exceeded the 50 billion mark, China's medicine is the only enterprise with a growth rate of more than 10%.
Shanghai Pharmaceuticals: In the first half of the year, the company achieved operating income of 87.2 billion yuan, of which the pharmaceutical industry achieved revenue of 11.675 billion yuan, down 2.24% YoY, and pharmaceutical business realized revenue of 75.490 billion yuan, down 6.38% YoY.
said that as the new crown outbreak stabilized, the company's overall business gradually resumed.
pharmaceutical industry, the company relies on a wealth of product variety resources, rapid response, improve and complement each other, the second quarter has achieved a steady recovery, 60 key varieties of sales revenue of 6.547 billion yuan, the average gross margin of 71.69 percent.
pharmaceutical business, mainly affected by the new crown epidemic, medical institutions in the first quarter of the business was more limited, resulting in a certain decline in pure sales, but from the second quarter on, commercial business has gradually resumed.
: First half of the company's revenue and net profit record high, revenue exceeded the 50 billion mark, net profit of more than 1 billion yuan.
For the rapid growth of performance, Kyusju Tong said, on the one hand, the company's general agent, general distribution varieties and medical equipment and other business rapidly increased, gross margin continued to increase, export foreign trade business breakthrough, financing costs fell, tax reduction and fee reduction policy results gradually appear, the company's management measures continue to strengthen;
.